Treatment of Anal Fistulas With Obsidian RFT® - a Retrospective Analysis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Closure rate anal fistula
研究概览
简要总结
The study conducted a retrospective analysis from January 2018 to December 2022 on patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna.
详细描述
Anal fistulas present a significant challenge in colorectal surgery, featuring abnormal passages between the anal canal and surrounding tissues. Traditional treatments, while effective, may risk damaging the anal sphincter complex and subsequent fecal incontinence. Sphincter-preserving techniques like autologous compound platelet-rich fibrin foam have gained popularity, offering potential for better functional outcomes in anal fistula treatment. In this context, our retrospective study aims to evaluate the efficacy and safety of autologous compound platelet-rich fibrin foam, specifically Obsidian RFT®, analyzing its success in fistula closure and functional outcomes, thus contributing to the advancement of sphincter-preserving methods in anal fistula management.
The study conducted a retrospective analysis from January 2018 to December 2022 on patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna.
Clinical diagnosis, complemented by radiographic imaging, was employed to confirm inconclusive cases.
Demographic, comorbidity, fistula characteristics, and postoperative data were collected from electronic records.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 99 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna
排除标准
- •unclear documentation
结局指标
主要结局
Closure rate anal fistula
时间窗: 24 months
anal fistula closure rate according to documentation in the patient administration system
次要结局
未报告次要终点
研究者
Dr. Christopher Dawoud
Principal Investigator; MD
Medical University of Vienna
